Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
- ATTRibute-CM is the only study to demonstrate a direct association between a prompt, sustained increase in serum TTR and survival in patients with ATTR-CM
- The open-label extension data for all ATTRibute-CM participants at Month 42 showed that rapid, sustained TTR stabilization from acoramidis demonstrated statistically significant reductions in ACM and CVH (including urgent outpatient treatment for heart failure exacerbations)
- In the ATTRibute-CM study, acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date in both ATTRv-CM and ATTRwt-CM patients:
- In as few as 3 months, the time to first event (ACM or CVH) durably separated relative to placebo- A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30- A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30
- Acoramidis is approved as Attruby™ by the U.S. FDA and is approved as BEYONTTRA® by the European Commission, the Japanese Pharmaceuticals and Medical Devices Agency, and the UK Medicines and Healthcare Products Regulatory Agency
PALO ALTO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ('BridgeBio' or the 'Company'), a new type of biopharmaceutical company focused on genetic diseases, published data showing that an early, sustained increase in serum transthyretin (TTR) levels predicted improved survival in ATTRibute-CM, its Phase 3 trial of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM). These findings were published in Journal of the American College of Cardiology (JACC) in the Special Focus Issue: Amyloid. Acoramidis is a selective, small molecule, orally administered, near-complete (≥90%) TTR stabilizer. These findings further support the thesis that ever better increases in serum TTR lead to ever better clinical outcomes and that early elevations in serum TTR are an important prognostic marker to inform treatment selection.
'Patients with ATTR-CM have progressive amyloid accumulation in the heart, which when untreated manifests as progressive heart failure, arrhythmias, and eventually can result in death. Increases in serum TTR seen with acoramidis therapy within 28 days of initiation and that were sustained with therapy, were associated with a decrease in all-cause mortality independent of baseline risk among subjects in the ATTRibute-CM trial. The increase in serum TTR is hypothesized to be due to a leftward shift in amyloidogenic TTR to a more stable tetrameric TTR. This is the first concrete evidence that there is a link between this rapid increase in serum TTR and survival. Such data may inform clinical practice, as early and sustained increases in serum TTR could represent a new potential ATTR disease-specific and prognostic biomarker that may further inform clinical decisions in optimizing care for ATTR-CM patients,' said Mathew Maurer, M.D. of Columbia University Irving Medical Center.
In patients with ATTR-CM, aging or an inherited variant can cause tetrameric TTR to destabilize and misfold, causing buildup of amyloid fibrils in the organs, specifically in the heart. These data demonstrate that by using acoramidis, a selective near-complete TTR stabilizer to bind serum TTR, a rapid and sustained increase in tetrameric TTR was independently associated with an improvement in overall survival, even after adjustment for known predictors like TTR variant status, baseline New York Heart Association (NYHA) functional class, baseline National Amyloidosis Centre (NAC) stage, and baseline serum TTR levels. Findings from the analysis included:
Treatment with acoramidis resulted in a sharp, significant early rise in serum TTR levels (mean 9.1 mg/dL) within 28 days which was sustained throughout the 30-month treatment period
For every 5-mg/dL increase in serum TTR level, the Cox proportional hazards model predicted a relative risk reduction of mortality of 26.6% and the logistic model predicted a relative reduction of 31.6% in odds of death through Month 30
An early increase in serum TTR levels on Day 28 of dosing was associated with reduced all-cause mortality (ACM) in univariate analysis, an association which persisted in multivariate analysis independent of TTR variant status, baseline NYHA functional class, baseline NAC stage, and baseline serum TTR levels
Logistic modeling demonstrated that among participants treated with acoramidis, the early increase in serum TTR was associated with reduced ACM, whereas there was no prompt and sustained increase in serum TTR observed in participants treated with placebo
Causal mediation analysis showed evidence that the acoramidis treatment effect on ACM probability through month 30 was fully mediated by the observed prompt and sustained increase in serum TTR
'This landmark analysis adds an incredibly important proof point to acoramidis's repository of compelling data that higher serum TTR levels are directly correlated with and mediate a reduction in mortality risk.' said Jonathan Fox, M.D., Ph.D., Chief Medical Officer of BridgeBio Cardiorenal. 'We believe that this will be an important measure for physicians treating ATTR-CM to consider and will be encouraging information for new and existing patients when reviewing options to treat their condition.'
Data from 42 months sustained treatment in the open-label extension study from ATTRibute-CM showed that rapid and sustained TTR stabilization from acoramidis demonstrated statistically significant reductions in both ACM and cardiovascular-related hospitalizations (CVH, which included urgent outpatient treatment for heart failure exacerbations). The continued curve separation of the composite endpoint of ACM and CVH emphasizes the importance of early and continuous treatment resulting in early and sustained clinical benefits. These data further underscore the hypothesis that ever better levels of stabilization lead to ever better clinical outcomes and emphasizes the importance of a prognostic biomarker, serum TTR, to inform decision making for patient care.
Acoramidis is approved as Attruby by the U.S. FDA and is approved as BEYONTTRA by the European Commission, Japanese Pharmaceuticals and Medical Devices Agency, and UK Medicines and Healthcare Products Regulatory Agency with all labels specifying near-complete stabilization of TTR.
About Attruby™ (acoramidis) INDICATION Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
IMPORTANT SAFETY INFORMATION Adverse Reactions Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).
About BridgeBio Pharma, Inc.BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, and YouTube.
BridgeBio Forward-Looking StatementsThis press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), which are usually identified by the use of words such as 'anticipates,' 'believes,' 'continues,' 'could,' 'estimates,' 'expects,' 'hopes,' 'intends,' 'may,' 'plans,' 'projects,' 'potential,' 'seeks,' 'should,' 'will,' and variations of such words or similar expressions. BridgeBio intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements, including statements regarding the potential for sustained increases in serum TTR to serve as a disease-specific and prognostic biomarker in ATTR-CM, the belief that early elevations in serum TTR are an important prognostic marker to inform treatment selection, the hypothesis that improved serum TTR stabilization is correlated with better clinical outcomes, and expectations about how these findings may guide physician decision-making and patient care, reflect BridgeBio's current views about its plans, intentions, expectations, and strategies, which are based on the information currently available to BridgeBio and on assumptions it has made. Although BridgeBio believes that its plans, intentions, expectations, and strategies as reflected in or suggested by these forward-looking statements are reasonable, it can give no assurance that such plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties, and assumptions, including, but not limited to: the risks associated with BridgeBio's dependence on third parties for development; regulatory authorities requiring additional studies or data to support the continued or expanded commercialization of acoramidis; whether data and results meet regulatory requirements or are sufficient for continued development, review, or approval; and whether other regulatory agencies agree with BridgeBio's strategies or data interpretations. These risks also include impacts from global health emergencies, such as delays in regulatory reviews and other activities, manufacturing and supply chain interruptions, adverse effects on healthcare systems, and disruption of the global economy; and the impacts of macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and in Israel and the Gaza Strip, increasing inflation rates, and fluctuating interest rates on BridgeBio's operations and expectations. Additional risks are described in the Risk Factors section of BridgeBio's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other filings with the U.S. Securities and Exchange Commission. Moreover, BridgeBio operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of BridgeBio's management as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in these statements. Except as required by applicable law, BridgeBio assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.
BridgeBio Media Contact:Bubba Murarka, Executive Vice Presidentcontact@bridgebio.com(650)-789-8220
BridgeBio Investor Contact:Chinmay Shukla, VP Strategic Financeir@bridgebio.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
The Walmart Frozen Shrimp Subject To Recall Due To Potential Radioactive Risks
The Food and Drug Administration (FDA) has protocols in place to detect contaminated foods before they enter the country. And, as of today, it has advised the public not to eat specific Great Value brand frozen raw shrimp sold in Walmart stores due to a possible radioactive risk. During regular inspections, the U.S. Customs & Border Protection (CBP) detected Cesium-137 (Cs-137) in a single sample of breaded shrimp, and all related containers and products were prevented from entering the United States. Cs-137 is a manmade radioisotope of cesium that's so widespread that it can be found in the air, soil, and food. After the FDA was alerted to the presence of this chemical, its own testing found about 68.48 Bq/kg — much lower than the 1200 Bq/kg threshold — in the breaded product (per the FDA advisory). Although the chemical wasn't found in other products tested, the agency says some could still be contaminated, representing a potential health concern but not an acute hazard. Since the investigation is ongoing, it's unclear if this frozen shrimp will become one of the worst seafood recalls that swept across America or even be among the biggest Walmart Great Value brand recalls in history. Read more: 14 Canned Foods To Stock Up On Before They Go Up In Price Specific Products Affected And What To Do The convenience and versatility of frozen shrimp make it a staple for many households. When you're looking for high-quality frozen shrimp to buy, though, reading the package label and looking for quality characteristics won't always protect you when some kind of contamination has occurred. The 2-pound bags of Great Value Raw Ez Peel Tail-On Farm-Raised White Vannamei Shrimp that the FDA is concerned about are processed by PT. Bahari Makmur Sejati, an Indonesian company that does business as BMS Foods. The lot codes are 8005540-1, 8005538-1, and 8005539-1 — all with a Best by Date of March 15, 2027. Exposure to possible low-level radiation from Cs-137 in these products could impact consumers' health with prolonged exposure. Because of that, the FDA suggests that customers who have purchased any of these packages throw them away; do not eat or serve them. It also advises that customers contact their healthcare teams if they have already eaten these products and experience adverse symptoms. Meanwhile, the FDA has recommended that Walmart issue a recall and that all distributors and retailers not sell or serve the products. Hungry for more? Sign up for the free Daily Meal newsletter for delicious recipes, cooking tips, kitchen hacks, and more, delivered straight to your inbox. Read the original article on The Daily Meal. Solve the daily Crossword
Bloomberg
3 hours ago
- Bloomberg
FDA Warns Against Eating Shrimp Brand, Citing Radioactive Matter
The US Food and Drug Administration has advised the public not to eat a brand of shrimp sold at Walmart Inc. over concerns about radioactive contamination. The agency told Walmart to pull three lots of raw frozen shrimp sourced from Indonesia after officials detected radioactive Cesium-137 in a shipment that did not enter the US, the FDA said in a statement on Tuesday. The isotope can lead to an elevated risk of cancer through repeated exposure to low doses, though the detected levels were not high enough to cause an acute risk, the FDA said.
Forbes
4 hours ago
- Forbes
As 90% Of Adults Stress Over Food Prices, Are Radioactive Shrimp A Result Of Cost Cutting?
Types of shrimp, tuna, stingray, and squid serve as a seafood chili sauce food menu at a food stall in Malang, East Java, Indonesia, on January 16, 2025. The seafood menu sells for USD 0.62 - USD 20.13 per package. (Photo by Aman Rochman/NurPhoto via Getty Images) NurPhoto via Getty Images As food costs rise, and tariffs began to come into play, are radioactive shrimp just the beginning? Yesterday, Walmart customers across 13 states were confronted this with an unsettling recall notice: raw frozen shrimp, sold under the retailer's Great Value brand, were being pulled from shelves after U.S. Food and Drug Administration (FDA) testing detected traces of Cesium-137, a man-made radioactive isotope. The discovery sparked a huge reaction online, a concern about food safety, and also what this episode reveals about a global seafood supply chain already under strain from tariffs, rising costs, and growing consumer mistrust. According to a press release by FDA officials, the contaminated shrimp originated from Indonesia and was processed by PT. Bahari Makmur Sejati also known as BMS Foods. Due to this recall, BMS Foods is now on the FDA's 'red list,' barred their products from the U.S. until further notice. The radioactive shrimp were detected at four U.S. ports—Los Angeles, Houston, Miami, and Savannah, GA—before an import alert was issued by the FDA. Walmart quickly recalled the affected products at the agency's direction, advising customers to discard lot numbers - 8005540-1, 8005538-1 and 8005539-1. While none of the products exceeded federal intervention thresholds for a recall, the suggestion of radioactive shrimp being sold and served on American dinner tables was enough to ignite public anxiety. A farmer dries fish in Suqian, China, on October 15, 2024. (Photo by Costfoto/NurPhoto via Getty Images) NurPhoto via Getty Images Indonesia is one of the world's top exporters of shrimp, and the United States is the largest purchaser of the crustacean worldwide. In the last 5 years, shrimp sales volume has increased from 275 million to 415 million pounds annually. Yet its aquaculture industry has faced repeated scrutiny for sanitary conditions. Environmental watchdogs have flagged processing facilities where seafood, particularly shrimp, is held in substandard environments, with overcrowded farm raised fishing ponds and questionable sanitary practices designed to cut costs - they are also creating condistions for contamination. And while Indonesia's Ministry of Maritime Affairs and Fisheries has vowed to introduce a quality and safety assurance system for marine and fisheries products to align with U.S. and global import standards, there is still work to be done. At the same time, American shrimpers along the Gulf Coast say they are being squeezed out by lower-priced imports, but they are looking forward to the tariffs to ease the pain. Shrimp caught in U.S. waters is generally more expensive, as domestic producers must follow stricter safety protocols. U.S. shrimpers have called on federal regulators to impose stronger protections, warning that unfair foreign trade practices and cheap imports are undermining their livelihood. But the impending tariffs on imported foods, may further disrupt seafood markets by driving up the costs. The Yale Budget Lab estimates that new tariffs could raise food costs by another 3%, with some categories like fresh produce initially jumping up by 7% and processed rice rising in price by 10.2% in the long term. Other items expected to cost more include cereal, meat and dairy products. For fish and shellfish, the added expense could tempt suppliers and distributors to cut costs elsewhere in the chain— through the reduction of quality controls, or cheaper processing. A shopper browses near the poultry section at a Walmart in Rosemead, California on December 19, 2024. An elderly patient in Louisiana is in "critical condition" with severe avian influenza, US authorities announced December 18, 2024, the first serious human case in the country as fears grow of a possible bird flu pandemic. Genetic sequencing revealed that the H5N1 virus in the patient belonged to the D1.1 genotype. This genotype has recently been detected in wild birds and poultry in the United States, and in human cases reported in Washington state and in the Canadian case, in British Columbia province (Photo by Frederic J. BROWN / AFP) (Photo by FREDERIC J. BROWN/AFP via Getty Images) AFP via Getty Images This shrimp recall is hitting at a time when Americans are already deeply uneasy about the cost and safety of their food. According to a recent Associated Press-NORC poll, nearly 90% of U.S. adults report being stressed out regarding the cost of groceries, making it the #1 financial worry ahead of housing, healthcare, and savings. The data backs up those fears. Over the past year, the Consumer Price Index shows food prices increasing faster than inflation with groceries and restaurants up 2.4% and 3.8% respectively. In just one year, from June 2024 to June 2025, egg prices rose 27.3%, while meats, poultry, and fish climbed 5.6%. Consumers are absorbing these increases at the same time as they are told to be vigilant about recalls—whether it's lettuce linked to E. coli, baby formula shortages, or, in this case, shrimp carrying detected radioactive material. Each incident chips away at trust in the food system. 21 May 2025, Lower Saxony, Cuxhaven: Crabs (North Sea prawns) already cooked on the crab cutter are loaded onto a truck in the port. German North Sea fishermen have suffered a setback in the legal dispute over special fishing bans. The EU court dismissed their lawsuit against the EU Commission's corresponding bans in their entirety. Photo: Sina Schuldt/dpa (Photo by Sina Schuldt/picture alliance via Getty Images) dpa/picture alliance via Getty Images So, are radioactive shrimp just the latest symptom of a broken supply chain—or an isolated event unlikely to be repeated? The answer may not be clear for months. The FDA says it is working with Indonesian authorities to trace the source of the contamination and in turn wants to tighten oversight. But the discovery underscores how global food systems, already stretched thin by inflation and tariffs, are vulnerable to lapses that would have once seemed unimaginable. While some consumers will point to the system working, others will refer to this incident as a cause for deepening anxieties that food is both too expensive and too unreliable. For businesses, it's a warning that cutting corners—even through complex, faraway supply chains—can end up costing far more in reputational damage than in upfront savings. Whether this was a one-off mishap or an early glimpse of what's ahead, it has landed squarely in the middle of America's growing uneasiness over what to eat, how much it costs, and whether the system designed to protect consumer interests can still be trusted.
